Development and Validation of an AI Foundation Model for CNS Tumor Classification
3d agoen
From the article
Conditions : Brain Tumors; Central Nervous System Neoplasms Sponsors : Huashan Hospital; Shandong Provincial Hospital Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
AI system Hetairos classifies 102 brain tumor subtypes from standard slides in minutes
A new AI system called Hetairos can classify 102 brain tumor subtypes from standard H&E tissue slides in minutes, compared to the current pr
AI tool analyzes tumour images to guide treatment for common brain cancer
Scientists at the University of Toronto and Mayo Clinic have developed an AI tool that analyzes images of tumour tissue to help identify men
36氪首发 | 物理AI公司获晶科能源、国投创新等数亿融资,要做全球能源基础设施“大脑”
36氪·2h ago

AI안경 쓰고 데이트 상대 여성 몰래 촬영·유포한 남성
매일경제·15h ago
UC San Diego AI Model Predicts Cancer Treatment Response from Tumor Genetics
UC San Diego researchers have developed an AI tool called iAtlas that can predict how a tumor will respond to treatment based solely on its
today.ucsd.edu·1mo ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·5d ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.